Navigation Links
Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases
Date:11/27/2007

System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' collaboration with Excaliard Pharmaceuticals and the discovery and development of Isis' antisense drugs for the local treatment of fibrotic diseases. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward- looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended September 30, 2007, which are on file with the SEC. Copies of th
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Recovery Resources Collaborates with Two Nonprofit Agencies for Children of Alcoholics Outreach Program
2. MU researchers to collaborate on $20 million project
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
5. EHRVA Members Collaborate to Demonstrate Interoperability Success at NCHICA
6. Rosecrance and Chicagos Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs
7. CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0
8. Free Access to Literature Data on Chagas Disease Offered Online: Collaborative Drug Discovery, Inc. provides Neglected Disease researchers with archive mine and collaborate access to small molecule bioactivity SAR data on parasitic disease
9. SAIC to Collaborate with UK Biometrics Institute
10. General Motors, Virginia Tech scientists collaborate to advance neuroinformatics
11. ThalesNano Inc. and the Christian Doppler Laboratory for Microwave Chemistry in Graz, Austria Collaborate on Flow Chemistry Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... New Jersey Plastic Surgeon and “NJ ... results. With over 30 years of experience in ... art, Dr. Rafizadeh knows what it takes to achieve ... Surgery involves the principles of proportion, harmony and balance. ... of comfort and personalized care from the moment a ...
(Date:5/28/2015)... May 28, 2015 Are policies that ... a hospital stay triggering financial pain for seniors? That’s ... Journal of Managed Care set to figure out, and ... federal rule change. , The study, “Observation Encounters and ... Vashi, MD, MPH, examined how Medicare policies that distinguish ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO ... in the role of president. , “ Bill Taaffe ... industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He will ... next phase of growth.” , Taaffe joined ICON’s U.S. ... employees to over 4,500 employees, achieving 12 consecutive years of ...
(Date:5/28/2015)... The Paw Project, an international nonprofit ... to educate the Oregon public about the harmful consequences ... Market Street and Park Avenue in Salem, Oregon's state ... Cats, Raise Your Hand,” depicts a human hand with ... graphic and anatomically-correct representation of the declaw surgery performed ...
(Date:5/28/2015)... May 28, 2015 Boston Celtics Legend ... Beth, both Genesis Foundation Board of Directors members, will ... Celebrity Fishing Tournament June 4-7. For the past 34 ... benefitting The Genesis Foundation for children by bringing together ... , The 34th John Havlicek Celebrity Fishing Tournament will ...
Breaking Medicine News(10 mins):Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2
... June 12 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... announced today that it has purchased three patents associated ... Inc. The patents relate to HIFU transducer arrays ...
... Denmark, Friday 12 June 2009: Three new studies have ... to be effective, with a good safety profile, in ... arthritis (JIA), and associated with improved Health-Related Quality of ... JIA. The data are being presented at the Paediatric ...
... directors of Abbott today declared a quarterly common dividend of 40 cents ... dividend to be paid by Abbott since 1924. The cash dividend ... of business on July 15, 2009. , , Abbott has increased ... increase earlier this year - and was again named to the ...
... summer months; 10% of all sales to be donated to ... Company (Nasdaq: TSTY ), makers of the Tastykake ... Stand Foundation (ALSF), by announcing the return of Alex,s Lemon ... leading organizations in the fight against childhood cancer, ALSF was ...
... June 2009: 92.8% of patients with systemic lupus erythematosus ... their physical and emotional quality of life (QoL), according ... at EULAR 2009, the Annual Congress of the European ... revealed that depression was the most significant factor shown ...
... FRIDAY, June 12 (HealthDay News) -- European researchers ... human,s needs. , The robots, built by ... project, were programmed to help a person put together ... process, it observes the person,s actions, such as what ...
Cached Medicine News:Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 2Health News:Misonix Announces the Purchase of Patents From ProRhythm, Inc. 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 4Health News:Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alex's Lemonade Stand Foundation 2Health News:Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alex's Lemonade Stand Foundation 3Health News:Anxiety and depression lower quality of life in majority of systemic lupus erythematosus patients 2Health News:A Robot That Reads Your Mind? 2
(Date:5/28/2015)... 28, 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... A. Martell , to the position of Executive Chairman. ... KaloBios Board of Directors. In this new role, he ... to refine and execute on the strategic plan to ... therapeutics for orphan oncology indications with high unmet medical ...
(Date:5/28/2015)... THE WOODLANDS, Texas , May 28, 2015 /PRNewswire/ ... announced today that Lexicon management will present at the ... at 8:00 a.m. Eastern Time in New ... of Lexicon,s clinical development programs and milestones. ... Lexicon,s website at www.lexpharma.com . An archived version ...
(Date:5/28/2015)... SOUTH SAN FRANCISCO, Calif. , May 28, 2015 ... the treatment of cancer, today announced that Sean ... at the upcoming Jefferies 2015 Global Healthcare Conference ... 2:30 p.m. EDT on Tuesday, June 2, 2015. Dr. ... including the company,s Precision cancer immunotherapy and Probody drug ...
Breaking Medicine Technology:KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5Lexicon To Present At The Jefferies 2015 Healthcare Conference 2
... FRANCISCO, July 21, 2011 ClinStar, LLC , ... and Eastern Europe to the pharmaceutical and biotechnology industry, ... speak at Marcus Evans 6th Annual Clinical Research ... FL.    (Logo: http://photos.prnewswire.com/prnh/20110719/SF36975LOGO ) ...
... July 21, 2011 Endologix, Inc. (NASDAQ: ELGX ... today announced financial results for the three and six months ... and Chief Executive Officer, said, "We are pleased with our ... our growth and new product development goals for 2011.  In ...
Cached Medicine Technology:ClinStar to Present on Conducting Clinical Trials in Russia 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 3Endologix Reports 22% Second Quarter 2011 Revenue Growth 4Endologix Reports 22% Second Quarter 2011 Revenue Growth 5Endologix Reports 22% Second Quarter 2011 Revenue Growth 6Endologix Reports 22% Second Quarter 2011 Revenue Growth 7Endologix Reports 22% Second Quarter 2011 Revenue Growth 8Endologix Reports 22% Second Quarter 2011 Revenue Growth 9
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
A pre-assembled, hexagonal, revolving tower display with two round 19.75" in diameter adjustable shelves. Enjoy 3.5 square feet of elegant shelf space for your products....
... is a multi-page database similar ... a database of patient information, ... adverse reactions, etc. and can ... and invoices that are necessary ...
A pre-assembled, rectangular shadow box/wall hanging display. It have 3 adjustable shelves with tempered glass, four 50 watt halogen top lights, laminated deck, dust resistant and electrical cord wit...
Medicine Products: